Quantitative determination of acrivastine and pseudoephedrine hydrochloride in pharmaceutical formulation by high performance liquid chromatography and derivative spectrophotometry

ALTUNTAŞ T., Zanooz S., Nebioglu D.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, cilt.17, sa.1, ss.103-109, 1998 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 1
  • Basım Tarihi: 1998
  • Doi Numarası: 10.1016/s0731-7085(97)00148-9
  • Dergi Adı: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.103-109
  • Anahtar Kelimeler: acrivastine, pseudoephedrine hydrochloride, derivative spectrophotometry, high performance liquid chromatography, pharmaceutical form, ULTRAVIOLET SPECTROPHOTOMETRY, ASSAY, MIXTURES, 2ND, SPECTROSCOPY, ACID, 1ST
  • Ankara Üniversitesi Adresli: Hayır

Özet

in this study, fourth derivative spectrophotometry and high performance liquid chromatography (HPLC) have been used and described for the quantitative determination of acrivastine (I) and pseudoephedrine hydrochloride (II) in their pharmaceutical capsules form (Duact(R)). In the former method, d(4)A/d lambda(4) values were measured in methanol at 315 and 269 nm for (I) and (II) respectively. The relative standard deviations (RSD) for the method were found to be 1.16% for (I) and 0.94% for (II). The latter method based on reversed phase HPLC system using LiChrosorb C18 analytical column. The mobile phase used for separation of (I), (II) and internal standard (p-hydroxymethylbenzoate) were the water/acetonitrile/methanol/perchloric acid/n-octylamine (500:130:25:13:0.3 v/v) and the detection of the compounds in the capsules were at 260 nm using UV detector. The RSD for the HPLC method were determined to be 0.79 and 0.88% for (I) and (II) respectively. The proposed methods, which give thoroughly comparable data, are simple, rapid, and allow precise and accurate results and could be used for commercial formulations containing acrivastine and pseudoephedrine hydrochloride in combination. (C) 1998 Elsevier Science B.V. All rights reserved.